Latest Breaking News On - Priteshj gandhi - Page 1 : comparemela.com

TellBio Announces Consecutive Manuscripts Showcasing Promising Translational and Clinical Applications of the TellDx Platform in Prostate Cancer and Tailoring Therapy in Advanced Breast Cancer

TellBio Announces Consecutive Manuscripts Showcasing Promising Translational and Clinical Applications of the TellDx Platform in Prostate Cancer and Tailoring Therapy in Advanced Breast Cancer
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesDaniel haberMehmet tonerDavid miyamotoShyamala maheswaranAnnie partisanoPriteshj gandhiAditya bardiaTelldx technology demonstrates efficacy of novel drugBreast cancer research programTellbio incTelldx technology demonstrates epigeneticBreast cancer researchHarvard medical schoolCancer researchHospital center

Circulating Tumor Cell (CTC) Isolation with TellDx

Single-cell proteomics can elucidate kinase activity in prostate cancer models Kinase activity in bone metastases and epithelial circulating.

United statesPriteshj gandhiMehmet tonerDaniela haberShyamala maheswaranAnnie partisanoCancer researchTellbio incHospital centerDrs david tingMassachusetts general hospital center

BioSpace Movers & Shakers, May 14

Published: May 13, 2021 By Alex Keown Akouos, Inc. – Kathy Reape was named chief development officer of Boston-based Akouos. Reape most recently served as chief medical officer at Spark Therapeutics where she oversaw clinical development, pharmacovigilance, and medical affairs activities. Reape was a key member of the team responsible for the development and commercialization of Luxturna, the first FDA-approved in vivo gene therapy approved for an inherited retinal disease caused by mutations in both copies of the RPE65 gene. Prior to Spark, Reape was senior vice president of clinical development focusing on global brands research and development at Allergan and Actavis. CARMAT – France-based CARMAT’s board of directors is reorganizing its governance and appointed three new directors. The company tapped Florent Battistella, David Coti and John B. Hernandez as directors. Battistella founded Nisima, a holding company, which holds stakes in various firms, notably

United statesQuadrucept bioVineet agarwalJanice olsonEinaro vik moKyle chiangPenrose therapeutxEli lillyPaul manningMann muhsinPriteshj gandhiMike stapleyAnnie partisanoCokey nguyenStephen squintoCarries cox

TellBio Unveils Next-Generation Liquid Biopsy Platform Focused on Early Detection and Treatment of Cancer

Published: May 10, 2021 Closes $5 million Series A financing Appoints Pritesh J. Gandhi, PharmD, as Chief Executive Officer and Annie Partisano, PharmD, MS, as Senior Vice President and Head of Operations Announces exclusive license of TellDx platform to Genetron Holdings Limited for China Secures Deployment of TellDx at ARUP Laboratories, Inc BEVERLY, Mass., May 10, 2021 (GLOBE NEWSWIRE) TellBio, Inc., a development stage biotechnology company focused on revolutionizing the detection and treatment of cancer through its unique and proprietary circulating tumor cell (CTC) technology, TellDx, and complementary therapeutics platform, TellRx, today announced the closing of a $5 million Series A financing. Concurrent with the close, the Company announced the appointments of Pritesh J. Gandhi, PharmD, as Chief Executive Officer (CEO) and Annie Partisano, PharmD, MS, as Senior Vice President and Head of Operations; an exclusive license of the TellDx platform to Genetron Holdi

United statesUniversity of massachusetts medical schoolRyo imaiSanofi genzymeRavi kapurDavid tingRichard petersPriteshj gandhiMehmet tonerAndy theurerShyamala maheswaranAnnie partisanoDaniel haberUniversity of utahAlnylam pharmaceuticalsGenetron holdings